Pro-Dex (PDEX) Stock Price, News & Analysis

Company Overview

Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.

Key Stats

• Today's Range: $40.71 to $42.34
• 50-Day Range: $38.41 to $53.50
• 52-Week Range: $19.00 to $70.26
• Volume: 32,371 shs
• Average Volume: 48,547 shs
• Market Capitalization: $132.71 million
• P/E Ratio: 14.54
• Dividend Yield: N/A
• Price Target: $56.00
• Consensus Rating: Buy

Pro-Dex Stock Analysis - MarketRank™

Pro-Dex scored higher than 63% of companies evaluated by MarketBeat, and ranked 366th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Pro-Dex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Pro-Dex has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 3.00%

Earnings Growth

Earnings for Pro-Dex are expected to grow by 3.00% in the coming year, from $2.00 to $2.06 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Pro-Dex is 14.54, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.60.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pro-Dex is 14.54, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 30.27.

Price to Book Value per Share Ratio

Pro-Dex has a P/B Ratio of 4.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.76% of the float of Pro-Dex has been sold short.

Short Interest Ratio / Days to Cover

Pro-Dex has a short interest ratio ("days to cover") of 4.9.

Change versus previous month

Short interest in Pro-Dex has recently increased by 11.87%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pro-Dex does not currently pay a dividend.

Dividend Growth

Pro-Dex does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.76% of the float of Pro-Dex has been sold short.

Short Interest Ratio / Days to Cover

Pro-Dex has a short interest ratio ("days to cover") of 4.9.

Change versus previous month

Short interest in Pro-Dex has recently increased by 11.87%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

Pro-Dex has a news sentiment score of 1.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Pro-Dex this week, compared to 1 article on an average week.

Search Interest

4 people have searched for PDEX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

Only 5 people have added Pro-Dex to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pro-Dex insiders have not sold or bought any company stock.

Percentage Held by Insiders

47.50% of the stock of Pro-Dex is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 15.28% of the stock of Pro-Dex is held by institutions.

PDEX Stock Analysis - Frequently Asked Questions

How have PDEX shares performed this year?

Pro-Dex's stock was trading at $46.75 at the beginning of 2025. Since then, PDEX stock has decreased by 12.9% and is now trading at $40.71.

How were Pro-Dex's earnings last quarter?

Pro-Dex, Inc. (NASDAQ:PDEX) released its earnings results on Thursday, May, 1st. The medical instruments supplier reported $0.98 earnings per share for the quarter, topping analysts' consensus estimates of $0.47 by $0.51. The medical instruments supplier earned $17.41 million during the quarter, compared to analysts' expectations of $17.70 million. Pro-Dex had a net margin of 14.61% and a trailing twelve-month return on equity of 29.08%.

Who are Pro-Dex's major shareholders?

Top institutional investors of Pro-Dex include Geode Capital Management LLC (1.58%), JPMorgan Chase & Co. (1.10%), Ritholtz Wealth Management (0.65%) and D.A. Davidson & CO. (0.32%). Insiders that own company stock include Alisha Charlton and Angelita Rebamontan Domingo.
View institutional ownership trends.

How do I buy shares of Pro-Dex?

Shares of PDEX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Pro-Dex own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pro-Dex investors own include NVIDIA (NVDA), Broadcom (AVGO), Novo Nordisk A/S (NVO), Adobe (ADBE), ServiceNow (NOW), Arista Networks (ANET) and Jabil (JBL).

Company Calendar

• Last Earnings: 5/01/2025
• Today: 8/14/2025
• Next Earnings (Estimated): 9/04/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED/DENTAL - SUPP
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:PDEX
• CIK: 788920
• Web: www.pro-dex.com
• Phone: (949) 769-3200
• Fax: 949-769-3281
• Employees: 140
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Pro-Dex: $56.00
• High Price Target: $56.00
• Low Price Target: $56.00
• Potential Upside/Downside: +37.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.80
• Trailing P/E Ratio: 14.54
• Forward P/E Ratio: 20.36
• P/E Growth: N/A
• Net Income: $2.13 million
• Net Margins: 14.61%
• Pretax Margin: 19.32%
• Return on Equity: 29.08%
• Return on Assets: 16.19%

Debt

• Debt-to-Equity Ratio: 0.28
• Current Ratio: 2.73
• Quick Ratio: 1.45

Sales & Book Value

• Annual Sales: $53.84 million
• Price / Sales: 2.46
• Cash Flow: $0.99 per share
• Price / Cash Flow: 41.17
• Book Value: $9.03 per share
• Price / Book: 4.51

Miscellaneous

• Outstanding Shares: 3,260,000
• Free Float: 1,712,000
• Market Cap: $132.71 million
• Optionable: Not Optionable
• Beta: 0.19